PDF(Pubmed)
Abstract：
To describe the characteristics of patients with new-onset headache following SARS-CoV-2 infection.
SARS-CoV-2 infection leads to several neurological manifestations, and headache is a frequent and disabling symptom, both exacerbating pre-existing headache syndromes and causing new-onset ones.
Patients with new-onset headache after SARS-CoV-2 infection with consent to participate were included, while those ones with previous headaches were excluded. The temporal latency of headache after infection, pain characteristics, and concomitant symptoms were analysed. Moreover, the efficacy of acute and preventive medications was explored.
Eleven females (median age 37.0 [10.0-60.0] years old) were included. In most cases, headache onset occurred with the infection, the location of pain varied, and the quality was either pulsating or tightening. Headache was persistent and daily in 8 patients (72.7%), while it occurred in episodes in the remaining subjects. Baseline diagnoses were new daily persistent headache (36.4%), probable new daily persistent headache (36.4%), probable migraine (9.1%), and migraine-like headache secondary to COVID-19 (18.2%). Ten patients received one or more preventive treatments and six of them showed an improvement.
New-onset headache following COVID-19 is a heterogenous condition with uncertain pathogenesis. This type of headache can become persistent and severe, with a wide spectrum of manifestations (new daily persistent headache being the most represented one) and variable response to treatment.
SARS-CoV-2 infection leads to several neurological manifestations, and headache is a frequent and disabling symptom, both exacerbating pre-existing headache syndromes and causing new-onset ones.
Patients with new-onset headache after SARS-CoV-2 infection with consent to participate were included, while those ones with previous headaches were excluded. The temporal latency of headache after infection, pain characteristics, and concomitant symptoms were analysed. Moreover, the efficacy of acute and preventive medications was explored.
Eleven females (median age 37.0 [10.0-60.0] years old) were included. In most cases, headache onset occurred with the infection, the location of pain varied, and the quality was either pulsating or tightening. Headache was persistent and daily in 8 patients (72.7%), while it occurred in episodes in the remaining subjects. Baseline diagnoses were new daily persistent headache (36.4%), probable new daily persistent headache (36.4%), probable migraine (9.1%), and migraine-like headache secondary to COVID-19 (18.2%). Ten patients received one or more preventive treatments and six of them showed an improvement.
New-onset headache following COVID-19 is a heterogenous condition with uncertain pathogenesis. This type of headache can become persistent and severe, with a wide spectrum of manifestations (new daily persistent headache being the most represented one) and variable response to treatment.
摘要：
目的：描述SARS-CoV-2感染后新发头痛患者的特征。
背景：SARS-CoV-2感染导致几种神经系统表现，头痛是一种常见的致残症状，既加剧了先前存在的头痛综合征，又导致了新发作的头痛综合征。
方法：纳入同意参与的SARS-CoV-2感染后新发头痛患者，而那些以前头痛的被排除在外。感染后头痛的潜伏期，疼痛的特点，并对伴随症状进行了分析。此外，探讨了急性和预防性药物的疗效.
结果：包括11名女性（中位年龄37.0[10.0-60.0]岁）。在大多数情况下,头痛发作与感染有关，疼痛的位置各不相同，质量要么是脉动的，要么是紧缩的。8例(72.7%)患者每天持续头痛,而它发生在其余受试者的发作中。基线诊断为新的每日持续性头痛（36.4％），可能是新的每日持续性头痛（36.4％），可能的偏头痛（9.1％），和COVID-19继发的偏头痛样头痛（18.2%）。10名患者接受了一种或多种预防性治疗，其中6名患者表现出改善。
结论：COVID-19后新发头痛是一种异质性疾病，发病机制不确定。这种类型的头痛可以变得持续和严重，具有广泛的表现（新的每日持续性头痛是最有代表性的一种）和对治疗的可变反应。
背景：SARS-CoV-2感染导致几种神经系统表现，
方法：纳入同意参与的SARS-CoV-2感染后新发头痛患者，
结果：包括11名女性（中位年龄37.0[10.0-60.0]岁）。
结论：COVID-19后新发头痛是一种异质性疾病，发病机制不确定。
